Atopic dermatitis, also known as eczema, is a skin condition that causes red, itchy, and scaly patches on the skin. It affects people of all ages, but it's more common in children. We don't know exactly what causes it, but it's believed to be caused by a mix of things like genes, environmental factors, allergens, and irritants. Atopic dermatitis can make people feel uncomfortable and unhappy, but there are some treatments available to help manage the symptoms.
However, many people with moderate-to-severe atopic dermatitis still have trouble managing their symptoms. A clinical trial tested a new treatment that combines two medicines called lebrikizumab and topical corticosteroids. The trial showed that this treatment improved outcomes in people with moderate-to-severe atopic dermatitis more than using topical corticosteroids alone.
Lebrikizumab is a type of medicine that stops a protein called interleukin-13 from developing. This protein is believed to play a role in the development of atopic dermatitis. The trial was done with 211 patients who had moderate-to-severe atopic dermatitis. The patients were from Germany, Poland, Canada, and the United States. The trial was done over a year and a half, from February 3, 2020, to September 16, 2021.